Fujifilm Diosynth Biotechnologies has agreed to reserve manufacturing capacity for a future Covid-19 therapy developed through the the COVID-19 Therapeutics Accelerator.
This programme was launched in March by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to remove barriers to drug development, and therefore speed up the therapeutic response to the novel coronavirus pandemic.
The manufacturing space reserved by Fujifilm Biotech in its facility in Hillerød, Denmark will be to support the supply of Covid-19 drugs to developing countries.
Fujifilm Biotech chief business officer Andy Fenny said: “Humanity is facing one of its most challenging times in recent history.
"Resolution calls for a global effort in collaboration between public, private and charitable entities.
“This partnership allows Fujifilm to deploy its leading technical expertise and significant production capacity to have a meaningful impact in the fight against this pandemic.”